Inactive Instrument

Karo Pharma AB (publ) Stock price

Equities

KARO

SE0007464888

Pharmaceuticals

Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 48 19-06-30
Director of Finance/CFO 49 19-09-30
Chief Tech/Sci/R&D Officer 42 18-12-31
Members of the board TitleAgeSince
Director/Board Member 67 20-12-31
Director/Board Member 66 19-10-30
Director/Board Member 58 20-05-24
More insiders
Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company's pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer treatment; ERbeta multiple sclerosis (MS), which specializes in the autoimmune disease MS treatment; and Related Orphan Receptor Gamma (RORgamma), which is responsible for the nuclear receptors application in treatment of autoimmune disease, such as rheumatoid arthritis and psoriasis. The Company collaborates with Pfizer, 4D Science, and Merck, among others. Its trademarks portfolio includes Karo Bio, BioKey, BioKey Assay and Molecular Braille. The Company operates Karo Bio Research AB, Karo Bio Discovery AB, Kommanditbolaget Odenplan Fastigheter, Tanomed AB, MedCore AB and Medireduce AB as subsidiaries.
More about the company
  1. Stock
  2. Equities
  3. Stock Karo Pharma AB (publ) - Nasdaq Stockholm